Peptides · Therapeutic Peptides
Main Therapeutic Peptides
39 Main Therapeutic Peptides products available from Unibest, part of our therapeutic peptides portfolio.
Available products
39 products currently listed. Request specifications, analytical data or a quotation for any item below.
| Product Name | CAS No. | Comments |
|---|---|---|
| Semaglutide | 910463-68-2 | Originator：Novo Nordisk Approver indications：Obesity,Overweight,Type II diabetes Target：GLP1R |
| Tirzepatide | 2023788-19-2 | Originator：ELI LILLY AND CO Approver indications：Type II diabetes Target：GLP-1R/GIPR |
| Linaclotide | 851199-59-2 | Originator：ABBVIE INC Approver indications：IBS-C/CIC/ FC Target：GC-C |
| Desmopressin acetate | 16789-98-3 | Originator：Ferring Pharmaceuticals Approver indications：Central/nephrogenic diabetes insipidus/ nocturnal enuresis Target：V2 receptor |
| Plecanatide | 467426-54-6 | Originator：SALIX PHARMACEUTICALS INC Approver indications：IBS-C/CIC Target：GC‑C |
| Oxytocin | 50-56-6 | Originator：SANDOZ INC Approver indications：Labor induction & augmentation/Postpartum hemorrhage/Incomplete abortion Target：OXTR |
| Abaloparatide | 247062-33-5 | Originator：RADIUS HEALTH INC Approver indications：Postmenopausal women with osteoporosis at high risk for fracture Target：PTH1R |
| Eptifibatide | 188627-80-7 | Originator：MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC Approver indications：ACS/PCI Target：GP IIb/IIIa |
| Lanreotide | 108736-35-2 | Originator：IPSEN PHARMA BIOTECH SAS Approver indications：Acromegaly Target：SSTR2、SSTR5 |
| Liraglutide | 204656-20-2 | Originator：NOVO NORDISK INC Approver indications：Type II diabetes mellitus Target：GLP-1R |
| Octreotide acetate | 83150-76-9 | Originator：NOVARTIS Approver indications：Acromegaly Target：SSTR2、SSTR5 |
| Icatibant | 30308-48-4 | Originator：TAKEDA PHARMACEUTICALS USA INC Approver indications：HAE Target：Bradykinin B2 receptor |
| Enfuvirtide | 15919-65-0 | Originator：HOFFMANN LA ROCHE INC Approver indications：Treatment-experienced patients with HIV-1 infection Target：HIV‑1 gp41 |
| Teduglutide | 197922-42-2 | Originator：TAKEDA PHARMACEUTICALS USA INC Approver indications：Short Bowel Syndrome Target：GLP-2R |
| Teriparatide | 12583-68-5 | Originator：ELI LILLY AND CO Approver indications：Osteoporosis in patients at high risk of fractures Target：PTH1 receptor |
| Cetrorelix acetate | 120287-85-6/130143-01-0 | Originator：EMD SERONO INC Approver indications：Inhibition of premature LH surges Target：GnRH-R |
| Ziconotide acetate | 107452-89-1 | Originator：TERSERA THERAPEUTICS LLC Approver indications：The management of severe chronic pain Target：CaV2.2 |
| Sincalide | 25126-32-3 | Originator：BRACCO DIAGNOSTICS INC Approver indications：Stimulate gallbladder contraction/Stimulate pancreatic secretion/Accelerate the transit of a barium meal through the small bowel Target：CCK1R |
| Vasopressin | 11000-17-2 | Originator：ENDO OPERATIONS LTD Approver indications：Increase blood pressure Target：vascular V1 receptors |
| Pramlintide acetate | 196078-30-5 | Originator：ASTRAZENECA AB Approver indications：For use in combination with insulin in patients with type 1 and type 2 diabetes to improve postprandial glycemic control. Target：AMY receptor |
| Degarelix acetate | 214766-78-6 | Originator：FERRING PHARMACEUTICALS INC Approver indications：Advanced prostate cancer Target：GnRH receptor |
| Lypressin | 50-57-7 | Originator：NOVARTIS PHARMACEUTICALS CORP Approver indications：Central Diabetes Insipidus Target：AVPR2 |
| Bivalirudin | 128270-60-0 | Originator：SANDOZ INC Approver indications：Thrombin inhibitor Target：Thrombin, F2 |
| Protirelin | 24305-27-9 | Originator：ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV Approver indications：Diagnostic Test Target：TRH-R |
| Terlipressin acetate | 14636-12-5 | Originator：MALLINCKRODT PHARMACEUTICALS IRELAND LTD Approver indications：HRS-1 Target：V1 Receptor |
| Ganirelix acetate | 123246-29-7 | Originator：ORGANON USA LLC A SUB OF ORGANON AND CO Approver indications：Preventing an early LH surge during ovarian stimulation cycles (COH) Target：GnRH receptor |
| Teriparatide acetate | 52232-67-4 | Originator：SANOFI AVENTIS US LLC Approver indications：/ Target：/ |
| Glucagon HCL | 11140-85-5 | Originator：ELI LILLY AND CO Approver indications：Severe hypoglycemia Target：Glucagon receptor |
| Vosoritide | 1480724-61-5 | Originator：BIOMARIN PHARMACEUTICAL INC Approver indications：Achondroplasia Target：NPR‑B |
| Octreotide Acetate | 79517-01-4 | Originator：NOVARTIS PHARMACEUTICALS CORP Approver indications：Acromegaly/Carcinoid Syndrome/VIPoma Target： SSTR2/SSTR5 |
| Triptorelin Pamoate | 124508-66-3 | Originator：VERITY PHARMACEUTICALS INC Approver indications：Prostate cancer Target：GnRH receptor |
| Goserelin Acetate | 145781-92-6 | Originator：TERSERA THERAPEUTICS LLC Approver indications：Carcinoma of the prostate/Palliative treatment of advanced carcinoma of the prostate / The management of endometriosis/Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding/Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women Target：GnRH receptor |
| Degarelix | 214766-78-6 | Originator：FERRING PHARMACEUTICALS INC Approver indications：Advanced Hormone-dependent Prostate Cancer。 Target：GnRH receptor |
| Carbetocin | 37025-55-1 | Originator：Ferring Pharmaceuticals Approver indications：Postpartum hemorrhage Target：Oxytocin receptor |
| Nesiritide | 124584-08-3 | Originator：SCIOS LLC Approver indications：Treatment of acutely decompensated chronic congestive heart failure with dyspnea at rest Target：NPR‑A |
| Glatiramer Acetate | 147245-92-9 | Originator：TEVA PHARMACEUTICALS USA Approver indications：Relapsing forms of multiple sclerosis (MS) Target：Th2 type T cells/Phagocytes-mixed T cells |
| Glucagon | 16941-32-5 | Originator：ELI LILLY AND CO Approver indications：Severe hypoglycemia Target：GCGR |
| Abarelix | 183552-38-7 | Originator：SPECIALITY EUROPEAN PHARMA LTD Approver indications：Advanced prostate cancer Target：GnRH |
| Etelcalcetide | 1262780-97-1 | Originator：KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC Approver indications：Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis Target：CaSR |
Related Therapeutic Peptides subcategories
Need main therapeutic peptides?
Send the specification, quantity and intended application. We will confirm availability, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →